[Prevalence of Candida albicans and Candida non-albicans in clinical samples during 1999-2001].
The importance of epidemiological monitoring of yeasts involved in pathologic processes is unquestionable due to the increase of these infections over the last decade, the changes observed in species causing candidiasis, and empirical antifungal treatment. At the Mycology Center, 1006 isolates from a wide range of clinical samples were studied during 1999-2001. Candida albicans (40.3%) was the most isolated species, although, the Candida no albicans species with 54.9% showed the major prevalence. In blood cultures Candida parapsilosis (34.9%), C. albicans (30.2%) and C. tropicalis (25.6%) were recovered most frequently while C. glabrata represented only 2.3%. C. albicans with 60%-80% was the predominant specie in mucosal surface. We also detected Candida mediastinistis, which alert us over the importance at this location. Urinary tract infections caused by yeasts were more frequent in hospitalized patients, being C. albicans (47.7%), the most commonly isolated, followed by C. glabrata (24.8%) and C. tropicalis (20.0%). In the candidal onychomycoses, C. parapsilosis (37.7%) outplaced C. albicans (22.0%). Fluconazole susceptibility studies of Candida species allowed us to conclude that the majority of C. albicans islolates are susceptible, and that the highest resistance averages were observed in C. glabrata (21.41%) and C. krusei (69.23%).
Mujica
M T
MT
Centro de Micología, Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, 1121 Ciudad Autónoma de Buenos Aires, Argentina. micología@fmed.uba.ar
Finquelievich
J L
JL
Jewtuchowicz
V
V
Iovannitti
C A
CA
D000935:Antifungal Agents / Q000494:pharmacology; D001118:Argentina / Q000453:epidemiology; D001826:Body Fluids / Q000382:microbiology; D002175:Candida / Q000187:drug effects / Q000302:isolation & purification*; D002176:Candida albicans / Q000187:drug effects / Q000302:isolation & purification*; D041221:Candida glabrata / Q000187:drug effects / Q000302:isolation & purification; D041022:Candida tropicalis / Q000187:drug effects / Q000302:isolation & purification; D002177:Candidiasis / Q000453:epidemiology* / Q000382:microbiology; D002179:Candidiasis, Cutaneous / Q000382:microbiology; D002181:Candidiasis, Vulvovaginal / Q000382:microbiology; D002406:Catheterization, Peripheral; D025141:Drug Resistance, Fungal; D005260:Female; D015725:Fluconazole / Q000494:pharmacology; D016469:Fungemia / Q000382:microbiology; D006801:Humans; D008297:Male; D008480:Mediastinitis / Q000382:microbiology; D009092:Mucous Membrane / Q000382:microbiology; D014009:Onychomycosis / Q000382:microbiology; D009928:Organ Specificity; D015995:Prevalence; D012189:Retrospective Studies; D013045:Species Specificity; D014552:Urinary Tract Infections / Q000382:microbiology
D000935:Antifungal Agents; D015725:Fluconazole